Pursuant to Regulation 29, 33 read with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Fredun Pharmaceuticals has informed that the meeting of the Board of Directors of the company is scheduled to be held on Monday 16th May, 2022 to consider and approve the following: Audited Financial Results for the last quarter and financial year ended March 31, 2022 along with the Statement of Assets and Liabilities and Cash Flow statement as on that date, Audited Financial Statements for the Financial Year ended March 31, 2022 and Recommend dividend for the Financial Year ended March 31, 2022 subject to the approval of the Shareholders at the ensuing Annual General Meeting of the Company. Further, in continuation of its intimation dated March 31, 2022 and pursuant to Company's ‘Code of Conduct’ formed under the Securities and Exchange Board of India (Prohibition of Insider Trading Regulations, 2015 and amendments thereunder, the trading window for dealing in the securities of the Company has been closed from April 01, 2022 and it shall remain closed until forty-eight hours after the date of declaration of results for the quarter and year ended March 31, 2022. The same has been circulated to the Directors, Key Managerial Personnel, Employees of the Company and their immediate relatives.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1494.95 |
Dr. Reddys Lab | 5882.45 |
Cipla | 1487.45 |
Zydus Lifesciences | 1087.65 |
Lupin | 1631.60 |
View more.. |